Merck Sharp + Dohme Corp.

Other

Anthony J Roecker

Paul J Coleman

Mark E Layton

Swati P Mercer

Thomas S Reger

John D Schreier

Christopher D Cox

Deping Wang

Thomas J Greshock

Jeffrey M Bergman

James J Mulhearn

Ting Zhang

Dansu Li

Philippe G Nantermet

Liangqin Guo

Ronald M Kim

Rajan Anand

Michael J Kelly, Iii

Walter Won

Gang Zhou

Scott D Kuduk

Xuanjia Peng

Joseph E Pero

Tianying Jian

Xiu Wang

Ian M Bell

Mark E Fraley

Melissa S Egbertson

Christopher S Burgey

Izzat Tiedje Raheem

Andrew John Harvey

Michael J Breslin

Dharam Paul

Junying Zheng

Scott E Wolkenberg

Lianyun Zhao

Zhijian Zhao

Brian T Campbell

John E Stelmach

Brendan M Crowley

Kenneth J Leavitt

Kevin F Gilbert

Christophe Morice

Belinda C Huff

Michael A Rossi

Georgia B McGaughey

Jean-Marie Contreras

Pablo De Leon

Kristen L G Jones

Justin T Steen

Fabrice Garrido

Christophe Joseph

Hannah D Fiji

Patrick Bazzini

Swati I P Mercer

Mamio Christa Mattern

Aurelie Witzel

James Fells

Michael J Iii Kelly

Swati Pal Mercer

Hannah Fiji

Georgia B Mcgaughey

Disclosed are compounds of Formula A, or a salt thereof: Wherein 'A', R, R, R, R, and Rare as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch and neuropathic pain disorders using the same.

Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels

The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and Rto Rare defined herein, which compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same. 

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same. 

Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-1 or their salts, and methods of treating pain (e.g. chronic pain), or cough or itch disorders using the same. 

N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof: wherein R, R, and E are defined herein, which compounds have properties for inhibiting Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Bridged diazepane orexin receptor antagonists

The present invention is directed to diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the diazepane compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Diazepane orexin receptor antagonists

Disclosed are compounds of Formula A-a, or a salt thereof: Where 'B' and 'R' through &#x201c;R&#x201d; are as defined herein, which compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-a or their salts, and methods of treating neuropathic pain disorders using the same. 

Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula (A) or a salt thereof, wherein 'Het', R, and Rare defined herein, which have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (A) or their salts, and methods of treating neuropathic pain disorders using the same. 

Benzoxazolinone compounds with selective activity in voltage-gated sodium channels

The present invention is directed to isoxazolopyndine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the isoxazolopyndine compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Isoxazolopyridine orexin receptor antagonists

The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

2,5-disubstituted piperidine orexin receptor antagonists

The present invention is directed to pyridazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Pyridazine carboxamide orexin receptor antagonists

The present invention is directed to bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Bridged diazepan orexin receptor antagonists

The present invention is directed to isonicotinamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Isonicotinamide orexin receptor antagonists

Growing community of inventors

North Wales, PA, United States of America

Anthony J Roecker